A Phase 2 interventional study of Prasugrel and Clopidogrel in Coronary Artery Disease, sponsored by Eli Lilly and Company. Completed at 16 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2010-08-31.
Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 40 studies testing prasugrel in Coronary Artery Disease — 4 open to participants now, 4 under way, 1 of them phase 3. prasugrel · Coronary Artery Disease.
Among the 40 studies testing prasugrel in Coronary Artery Disease, this one is the 11th largest by enrollment, is one of 2 that started in 2006, is one of 4 in phase 2, and was the 3rd registered.
4,863 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.
Browse Coronary Artery Disease studies →4 of the 40 studies testing prasugrel in Coronary Artery Disease are open now, in 2 countries. Recruiting first, the newest first:
Cardiocentro Ticino · Sites in Switzerland
Ages 18+
University of Florida · Sites in United States
Ages 18+
University of Florida · Sites in United States
Ages 18+
University of Florida · Sites in United States
Ages 18–75
By country, each count listing its studies:
prasugrel: first FDA approval 2009 (EFFIENT), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →
Of the 588 Coronary Artery Disease studies recruiting now, 402 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 38 take children under 18; 48 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
40 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 2 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 201 is above the median of 124 across 3,010 interventional studies indexed under Coronary Artery Disease.
Median enrollment 84 across the 40 interventional studies. Of the 30 that completed or were terminated, 18 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 40 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
10 studies in Coronary Artery Disease by Eli Lilly and Company: 2 open now, 3 under way, 1 of them phase 3. Of 7 finished, 7 (100%) have results posted.
Among the 10 studies in Coronary Artery Disease by Eli Lilly and Company, this one is the 4th largest by enrollment, is one of 2 that started in 2006, is one of 5 in phase 2, and was the 3rd registered.
Eli Lilly and Company’s Coronary Artery Disease studies by the year they started, since 2004.
1 of the studies testing prasugrel in Coronary Artery Disease that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07025148University of FloridaDual Antiplatelet Therapy Escalation From Standard-dose Clopidogrel to Low-Dose Prasugrel in Patients With High Bleeding and Ischemic Risk Undergoing PCI: A Prospective, Randomized Pharmacodynamic Study (TAILOR-BLEED-2) | 2027-08-01 |
Add it to your calendar (.ics) → With an account.
Among the 40 studies testing prasugrel in Coronary Artery Disease, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Eli Lilly and Company’s 10 in Coronary Artery Disease:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to provide information of the relative potency of prasugrel and clopidogrel on platelet function studies, inflammation, and myocyte necrosis in subjects undergoing elective percutaneous coronary intervention (PCI).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
At least one of the following (a through c):
Functional study (exercise, or pharmacologic) within the past 8 weeks consistent with ischemia as manifested by at least one of the following:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
One time oral loading dose (LD) of 60-mg Prasugrel and placebo matched to clopidogrel (plus oral enteric coated aspirin 325 mg to 500 mg is recommended) followed by 10-mg Prasugrel and placebo matched to clopidogrel taken orally once a day for 14 days. Patients cross-over to 150 mg clopidogrel and placebo matched to prasugrel taken orally once a day for the next 14 days.
Drug: Prasugrel · Drug: Clopidogrel · Drug: Placebo for Prasugrel · Drug: Placebo for Clopidogrel
One time oral LD of 600 mg clopidogrel and placebo matched to prasugrel (plus oral enteric coated aspirin 325 mg to 500 mg is recommended) followed by 150 mg clopidogrel and placebo matched to prasugrel taken orally once a day for 14 days. Patients cross-over to 10 mg prasugrel and placebo tablets matched to clopidogrel taken orally once a day for the next 14 days.
Drug: Prasugrel · Drug: Clopidogrel · Drug: Placebo for Prasugrel · Drug: Placebo for Clopidogrel
Administered orally
Also known as: LY 640315, Effient, Efient
Administered orally
Administered orally
Administered orally
Inhibition of Platelet Aggregation (IPA) to 20 Micromolar (μM) Adenosine Diphosphate (ADP) at 6 Hours After the Loading Dose
IPA was defined as (1 - \[maximal platelet aggregation(MPA) at 6 hours after study drug treatment\]/\[MPA before drug treatment\]) x 100.
Time frame: 6 hours after loading dose
Inhibition of Platelet Aggregation to 20 μM Adenosine Diphosphate After 14 Days of Maintenance Dose Treatment
Measures IPA during maintenance dosing before and after cross-over for each therapy. IPA was defined as (1 - \[maximal platelet aggregation(MPA) at 14 days after study drug treatment\]/\[MPA before drug treatment\]) x 100.
Time frame: after 14 days of maintenance dosing
Inhibition of Platelet Aggregation to 20 μM Adenosine Diphosphate at 2 Hours After the Loading Dose
IPA was defined as (1 - \[maximal platelet aggregation (MPA) at 2 hours after study drug treatment\]/\[MPA before drug treatment\]) x 100.
Time frame: 2 hours after loading dose
Number of Participants With Non-Coronary Artery Bypass Graft (CABG) Thrombolysis in Myocardial Infarction (TIMI) Major or Minor Bleeding During the First Maintenance Dose Phase
Non-CABG-related TIMI major bleeding was any intracranial hemorrhage OR any clinically overt bleeding associated with a fall in hemoglobin \>=5 gm/dL. Non-CABG-related TIMI minor bleeding was any clinically overt bleeding associated with a fall in hemoglobin \>=3 gm/dL but \<5 gm/dL.
Time frame: after 14 days of treatment (before cross-over)
Number of Participants With Non-Coronary Artery Bypass Graft (CABG) Thrombolysis in Myocardial Infarction (TIMI) Major or Minor Bleeding During the Crossover Maintenance Dose Phase
Non-CABG-related TIMI major bleeding was any intracranial hemorrhage OR any clinically overt bleeding associated with a fall in hemoglobin \>=5 gm/dL. Non-CABG-related TIMI minor bleeding was any clinically overt bleeding associated with a fall in hemoglobin \>=3 gm/dL but \<5 gm/dL.
Time frame: 14 days after cross-over
Number of Participants With Major Adverse Cardiac Events (MACE) During the First Maintenance Dose Phase
Number of patients who met any of the following endpoints: cardiovascular death, myocardial infarction, stroke, subacute stent thrombosis, or urgent target vessel revascularization
Time frame: after 14 days of treatment (before cross-over)
Number of Participants With Major Adverse Cardiac Events During the Crossover Maintenance Dose Phase
Number of patients who met any of the following endpoints: cardiovascular death, myocardial infarction, stroke, subacute stent thrombosis, or urgent target vessel revascularization
Time frame: 14 days after cross-over
Number of Hyporesponsive Participants at 6 Hours After the Loading Dose
Number of patients with inhibition of platelet aggregation (IPA) with 20 uM adenosine diphosphate (ADP) \<20%
Time frame: 6 hours after loading dose
Number of Hyporesponsive Participants at the End of the First Maintenance Dose Phase
Number of patients with inhibition of platelet aggregation (IPA) with 20 uM adenosine diphosphate (ADP) \<20%
Time frame: From loading dose to day 15
Number of Hyporesponsive Participants at the End of the Crossover Maintenance Dose Phase
Number of patients with inhibition of platelet aggregation (IPA) with 20 uM adenosine diphosphate (ADP) \<20%
Time frame: 14 days after cross-over
Platelet Reactivity Index Percent (PRI%) Measured by Vasodilator-stimulated Phosphoprotein (VASP) at 2 Hours After the Loading Dose
VASP phosphorylation in response to prostaglandin E1 (PGE1) with and without ADP was determined by whole-blood flow cytometry and was expressed as a platelet reactivity index (PRI). PRI was defined as \[(MFI(with PGE1) - MFI (with PGE1 and ADP))/MFI(with PGE1) x 100\] where MFI is mean fluorescence index. A lower PRI indicates greater antiplatelet effect.
Time frame: 2 hours after loading dose
Platelet Reactivity Index Percent (PRI%) Measured by Vasodilator-stimulated Phosphoprotein (VASP) at 6 Hours After the Loading Dose
VASP phosphorylation in response to prostaglandin E1 (PGE1) with and without ADP was determined by whole-blood flow cytometry and was expressed as a platelet reactivity index (PRI). PRI was defined as \[(MFI(with PGE1) - MFI (with PGE1 and ADP))/MFI(with PGE1) x 100\] where MFI is mean fluorescence index. A lower PRI indicates greater antiplatelet effect.
Time frame: 6 hours after loading dose
Platelet Reactivity Index Percent (PRI%) Measured by Vasodilator-stimulated Phosphoprotein (VASP) 18 to 24 Hours After the Loading Dose
VASP phosphorylation in response to prostaglandin E1 (PGE1) with and without ADP was determined by whole-blood flow cytometry and was expressed as a platelet reactivity index (PRI). PRI was defined as \[(MFI(with PGE1) - MFI (with PGE1 and ADP))/MFI(with PGE1) x 100\] where MFI is mean flourescence index. A lower PRI indicates greater antiplatelet effect.
Time frame: 18 to 24 hours after loading dose
Platelet Reactivity Index Percent (PRI%) Measured by Vasodilator-stimulated Phosphoprotein (VASP) After 14 Days of Maintenance Dose Treatment
VASP phosphorylation in response to prostaglandin E1 (PGE1) with and without ADP was determined by whole-blood flow cytometry and was expressed as a platelet reactivity index (PRI). PRI was defined as \[(MFI(with PGE1) - MFI (with PGE1 and ADP))/MFI(with PGE1) x 100\] where MFI is mean fluorescence index. A lower PRI indicates greater antiplatelet effect.
Time frame: after 14 days of maintenance dosing
Myonecrosis Measure: Creatine Kinase-Myocardial Bands (CK-MB) at 6 Hours After the Loading Dose
Mean CK-MB at 6 hours after loading dose. CK-MB is a biomarker for myonecrosis
Time frame: 6 hours after loading dose
Myonecrosis Measure: Creatine Kinase-Myocardial Bands (CK-MB) 18 to 24 Hours After the Loading Dose
Mean CK-MB at 18-24 hours after loading dose. CK-MB is a biomarker for myonecrosis.
Time frame: 18 to 24 hours after loading dose
Myonecrosis Measure: Cardiac Troponin at 6 Hours After the Loading Dose
Mean troponin level at 6 hours after the loading dose. Troponin is a biomarker for myonecrosis.
Time frame: 6 hours after loading dose
Myonecrosis Measure: Cardiac Troponin 18 to 24 Hours After the Loading Dose
Mean troponin level at 18 to 24 hours after the loading dose. Troponin is a biomarker for myonecrosis.
Time frame: 18 to 24 hours after loading dose
| Milestone | Prasugrel to Clopidogrel | Clopidogrel to Prasugrel |
|---|---|---|
| Started | 102 | 99 |
| Received loading dose | 102 | 99 |
| Percutaneous coronary intervention (pci) | 55 | 57 |
| Started maintenance dose | 55 | 55 |
| Completed | 54 | 55 |
| Not completed | 48 | 44 |
| Withdrew: Not a pci patient | 47 | 42 |
| Withdrew: Withdrawal by subject | 1 | 2 |
| Milestone | Prasugrel to Clopidogrel | Clopidogrel to Prasugrel |
|---|---|---|
| Started | 54 | 55 |
| Completed | 54 | 55 |
| Not completed | 0 | 0 |
IPA was defined as (1 - \[maximal platelet aggregation(MPA) at 6 hours after study drug treatment\]/\[MPA before drug treatment\]) x 100.
| percent inhibition | Prasugrel | Clopidogrel |
|---|---|---|
| Inhibition of Platelet Aggregation (IPA) to 20 Micromolar (μM) Adenosine Diphosphate (ADP) at 6 Hours After the Loading Dose | 74.81 ± 13.01 | 31.77 ± 21.07 |
Measures IPA during maintenance dosing before and after cross-over for each therapy. IPA was defined as (1 - \[maximal platelet aggregation(MPA) at 14 days after study drug treatment\]/\[MPA before drug treatment\]) x 100.
| percent inhibition | Prasugrel | Clopidogrel |
|---|---|---|
| Inhibition of Platelet Aggregation to 20 μM Adenosine Diphosphate After 14 Days of Maintenance Dose Treatment | 61.34 ± 17.84 | 46.06 ± 21.34 |
IPA was defined as (1 - \[maximal platelet aggregation (MPA) at 2 hours after study drug treatment\]/\[MPA before drug treatment\]) x 100.
| percent inhibition | Prasugrel | Clopidogrel |
|---|---|---|
| Inhibition of Platelet Aggregation to 20 μM Adenosine Diphosphate at 2 Hours After the Loading Dose | 64.54 ± 20.43 | 20.32 ± 20.22 |
Non-CABG-related TIMI major bleeding was any intracranial hemorrhage OR any clinically overt bleeding associated with a fall in hemoglobin \>=5 gm/dL. Non-CABG-related TIMI minor bleeding was any clinically overt bleeding associated with a fall in hemoglobin \>=3 gm/dL but \<5 gm/dL.
| participants | Prasugrel | Clopidogrel |
|---|---|---|
| Number of Participants With Non-Coronary Artery Bypass Graft (CABG) Thrombolysis in Myocardial Infarction (TIMI) Major or Minor Bleeding During the First Maintenance Dose Phase | 2 | 0 |
Non-CABG-related TIMI major bleeding was any intracranial hemorrhage OR any clinically overt bleeding associated with a fall in hemoglobin \>=5 gm/dL. Non-CABG-related TIMI minor bleeding was any clinically overt bleeding associated with a fall in hemoglobin \>=3 gm/dL but \<5 gm/dL.
| participants | Clopidogrel | Prasugrel |
|---|---|---|
| Number of Participants With Non-Coronary Artery Bypass Graft (CABG) Thrombolysis in Myocardial Infarction (TIMI) Major or Minor Bleeding During the Crossover Maintenance Dose Phase | 0 | 0 |
Number of patients who met any of the following endpoints: cardiovascular death, myocardial infarction, stroke, subacute stent thrombosis, or urgent target vessel revascularization
| participants | Prasugrel | Clopidogrel |
|---|---|---|
| Number of Participants With Major Adverse Cardiac Events (MACE) During the First Maintenance Dose Phase | 2 | 1 |
Number of patients who met any of the following endpoints: cardiovascular death, myocardial infarction, stroke, subacute stent thrombosis, or urgent target vessel revascularization
| participants | Clopidogrel | Prasugrel |
|---|---|---|
| Number of Participants With Major Adverse Cardiac Events During the Crossover Maintenance Dose Phase | 1 | 0 |
Number of patients with inhibition of platelet aggregation (IPA) with 20 uM adenosine diphosphate (ADP) \<20%
| participants | Prasugrel | Clopidogrel |
|---|---|---|
| Number of Hyporesponsive Participants at 6 Hours After the Loading Dose | 0 | 21 |
Number of patients with inhibition of platelet aggregation (IPA) with 20 uM adenosine diphosphate (ADP) \<20%
| participants | Prasugrel | Clopidogrel |
|---|---|---|
| Number of Hyporesponsive Participants at the End of the First Maintenance Dose Phase | 1 | 7 |
Number of patients with inhibition of platelet aggregation (IPA) with 20 uM adenosine diphosphate (ADP) \<20%
| participants | Clopidogrel | Prasugrel |
|---|---|---|
| Number of Hyporesponsive Participants at the End of the Crossover Maintenance Dose Phase | 4 | 1 |
VASP phosphorylation in response to prostaglandin E1 (PGE1) with and without ADP was determined by whole-blood flow cytometry and was expressed as a platelet reactivity index (PRI). PRI was defined as \[(MFI(with PGE1) - MFI (with PGE1 and ADP))/MFI(with PGE1) x 100\] where MFI is mean fluorescence index. A lower PRI indicates greater antiplatelet effect.
| percent (%) platelet reactivity index | Prasugrel | Clopidogrel |
|---|---|---|
| Platelet Reactivity Index Percent (PRI%) Measured by Vasodilator-stimulated Phosphoprotein (VASP) at 2 Hours After the Loading Dose | 21.5 ± 27.06 | 75.0 ± 16.91 |
VASP phosphorylation in response to prostaglandin E1 (PGE1) with and without ADP was determined by whole-blood flow cytometry and was expressed as a platelet reactivity index (PRI). PRI was defined as \[(MFI(with PGE1) - MFI (with PGE1 and ADP))/MFI(with PGE1) x 100\] where MFI is mean fluorescence index. A lower PRI indicates greater antiplatelet effect.
| percent (%) platelet reactivity index | Prasugrel | Clopidogrel |
|---|---|---|
| Platelet Reactivity Index Percent (PRI%) Measured by Vasodilator-stimulated Phosphoprotein (VASP) at 6 Hours After the Loading Dose | 7.4 ± 16.66 | 68.4 ± 21.18 |
VASP phosphorylation in response to prostaglandin E1 (PGE1) with and without ADP was determined by whole-blood flow cytometry and was expressed as a platelet reactivity index (PRI). PRI was defined as \[(MFI(with PGE1) - MFI (with PGE1 and ADP))/MFI(with PGE1) x 100\] where MFI is mean flourescence index. A lower PRI indicates greater antiplatelet effect.
| percent (%) platelet reactivity index | Prasugrel | Clopidogrel |
|---|---|---|
| Platelet Reactivity Index Percent (PRI%) Measured by Vasodilator-stimulated Phosphoprotein (VASP) 18 to 24 Hours After the Loading Dose | 10.3 ± 15.63 | 64.3 ± 18.72 |
VASP phosphorylation in response to prostaglandin E1 (PGE1) with and without ADP was determined by whole-blood flow cytometry and was expressed as a platelet reactivity index (PRI). PRI was defined as \[(MFI(with PGE1) - MFI (with PGE1 and ADP))/MFI(with PGE1) x 100\] where MFI is mean fluorescence index. A lower PRI indicates greater antiplatelet effect.
| percent (%) platelet reactivity index | Prasugrel | Clopidogrel |
|---|---|---|
| Platelet Reactivity Index Percent (PRI%) Measured by Vasodilator-stimulated Phosphoprotein (VASP) After 14 Days of Maintenance Dose Treatment | 23.4 ± 19.19 | 43.8 ± 23.26 |
Mean CK-MB at 6 hours after loading dose. CK-MB is a biomarker for myonecrosis
| IU/L | Prasugrel | Clopidogrel |
|---|---|---|
| Myonecrosis Measure: Creatine Kinase-Myocardial Bands (CK-MB) at 6 Hours After the Loading Dose | 9.16 ± 8.3 | 8.13 ± 5.16 |
Mean CK-MB at 18-24 hours after loading dose. CK-MB is a biomarker for myonecrosis.
| IU/L | Prasugrel | Clopidogrel |
|---|---|---|
| Myonecrosis Measure: Creatine Kinase-Myocardial Bands (CK-MB) 18 to 24 Hours After the Loading Dose | 11.64 ± 8.22 | 11.16 ± 8.72 |
Mean troponin level at 6 hours after the loading dose. Troponin is a biomarker for myonecrosis.
| ng/ml | Prasugrel | Clopidogrel |
|---|---|---|
| Myonecrosis Measure: Cardiac Troponin at 6 Hours After the Loading Dose | 0.06 ± 0.204 | 0.05 ± 0.128 |
Mean troponin level at 18 to 24 hours after the loading dose. Troponin is a biomarker for myonecrosis.
| ng/ml | Prasugrel | Clopidogrel |
|---|---|---|
| Myonecrosis Measure: Cardiac Troponin 18 to 24 Hours After the Loading Dose | 0.12 ± 0.273 | 0.13 ± 0.277 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Prasugrel Before Cross-over | — | 8/102 (7.8%) | 40/102 (39.2%) |
| Clopidogrel Before Cross-over | — | 7/99 (7.1%) | 40/99 (40.4%) |
| Prasugrel After Cross-over | — | 1/55 (1.8%) | 16/55 (29.1%) |
| Clopidogrel After Cross-over | — | 3/53 (5.7%) | 12/53 (22.6%) |
| Event | Prasugrel Before Cross-over | Clopidogrel Before Cross-over | Prasugrel After Cross-over | Clopidogrel After Cross-over |
|---|---|---|---|---|
| Vessel puncture site haematomaGeneral disorders | 2/102 | 0/99 | 0/55 | 0/53 |
| Acute coronary syndromeCardiac disorders | 0/102 | 0/99 | 0/55 | 1/53 |
| Borrelia infectionInfections and infestations | 0/102 | 0/99 | 0/55 | 1/53 |
| Chronic obstructive pulmonmary diseaseRespiratory, thoracic and mediastinal disorders | 0/102 | 0/99 | 0/55 | 1/53 |
| TachycardiaCardiac disorders | 0/102 | 0/99 | 0/55 | 1/53 |
| Non-cardiac chest painGeneral disorders | 0/102 | 1/99 | 1/55 | 0/53 |
| Chest discomfortGeneral disorders | 0/102 | 1/99 | 0/55 | 0/53 |
| Chest painGeneral disorders | 0/102 | 1/99 | 0/55 | 0/53 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 0/102 | 1/99 | 0/55 | 0/53 |
| ExtrasystolesCardiac disorders | 0/102 | 1/99 | 0/55 | 0/53 |
| Event | Prasugrel Before Cross-over | Clopidogrel Before Cross-over | Prasugrel After Cross-over | Clopidogrel After Cross-over |
|---|---|---|---|---|
| HypotensionVascular disorders | 5/102 | 1/99 | 0/55 | 0/53 |
| Back painMusculoskeletal and connective tissue disorders | 4/102 | 4/99 | 2/55 | 0/53 |
| DyspepsiaGastrointestinal disorders | 1/102 | 4/99 | 0/55 | 0/53 |
| MyalgiaMusculoskeletal and connective tissue disorders | 0/102 | 4/99 | 1/55 | 0/53 |
| Chest painGeneral disorders | 4/102 | 3/99 | 2/55 | 2/53 |
| Groin painMusculoskeletal and connective tissue disorders | 4/102 | 1/99 | 0/55 | 0/53 |
| HaematomaVascular disorders | 4/102 | 1/99 | 1/55 | 0/53 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 1/102 | 2/99 | 1/55 | 2/53 |
| EpistaxisReproductive system and breast disorders | 3/102 | 2/99 | 2/55 | 0/53 |
| Musculoskeletal painMusculoskeletal and connective tissue disorders | 1/102 | 1/99 | 2/55 | 0/53 |
| Age, Categorical(Participants) | Prasugrel to Clopidogrel | Clopidogrel to Prasugrel | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 46 | 47 | 93 |
| >=65 years | 56 | 52 | 108 |
| Age Continuous(years) | Prasugrel to Clopidogrel | Clopidogrel to Prasugrel | Total |
|---|---|---|---|
| Mean | 64.0 ± 10.73 | 63.8 ± 9.38 | 63.9 ± 10.06 |
| Sex: Female, Male(Participants) | Prasugrel to Clopidogrel | Clopidogrel to Prasugrel | Total |
|---|---|---|---|
| Female | 29 | 22 | 51 |
| Male | 73 | 77 | 150 |
| Race/Ethnicity, Customized(participants) | Prasugrel to Clopidogrel | Clopidogrel to Prasugrel | Total |
|---|---|---|---|
| African | 3 | 4 | 7 |
| Caucasian | 97 | 94 | 191 |
| Native American | 2 | 0 | 2 |
| West Asian | 0 | 1 | 1 |
| Region of Enrollment(participants) | Prasugrel to Clopidogrel | Clopidogrel to Prasugrel | Total |
|---|---|---|---|
| France | 3 | 3 | 6 |
| Germany | 55 | 53 | 108 |
| Israel | 15 | 13 | 28 |
| United States | 29 | 30 | 59 |
The record gives a start of Aug 2006, a primary completion of Jun 2007 and a completion of Jun 2007. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2010, 3 years 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Prasugrel · Clopidogrel